Allergan

Allergan plc, a global pharmaceutical entity trading under the NYSE ticker AGN, operates as a unique leader within the Growth Pharma industry model. The company is dedicated to developing and delivering innovative treatments across various therapeutic areas. Its strategic focus centers on a best-in-class portfolio designed to address unmet medical needs, leveraging cutting-edge science and robust research and development capabilities. Allergan's commitment to advancing healthcare is underscored by its pursuit of novel therapeutic agents and treatments, aiming to improve patient outcomes worldwide. The company's operational scale is supported by a workforce of 500-1,000 employees, contributing to its global pharmaceutical endeavors. Meet Allergan's team to gain insights into the leadership driving these advancements. The company has achieved significant revenue, reporting $433.4M. While specific location counts are not detailed, Allergan maintains a global pharmaceutical presence, reflecting its international scope and market reach. Its product development pipeline includes key areas such as eye care preparations and other specialized pharmaceutical agents, positioning it as a significant player in the healthcare sector. The company's R&D centers are crucial hubs for scientific innovation and the creation of next-generation therapies.